HUTCHMED (China) Ltd
HUTCHMED (China) Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It has operations spanning China and international markets, with products and development programs supported by in-house R&D, third-party partners, and manufacturing arrangements.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved cancer drugs sold through partners or direct supply channels.
Investigational cancer therapies in global and China development.
Drug candidates for immunological diseases and related research programs.
Third-party pharmaceutical distribution and other non-core activities in China.
Tuotteet
Raportoitu · osuus liikevaihdosta- Goods Distribution47,9 %
- Marketed Products18,3 %
- Other Collaboration Royalties Revenue12,5 %
- Commercialization Services8,3 %
- License and Collaborations Manufacturing Supply5,7 %
- Muut7,3 %
Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Customers include hospitals, physicians, and patients accessing approved oncology medicines in China and other markets through commercial channels and partners. The company also serves pharmaceutical partners and distributors through its distribution venture, as well as clinical investigators and trial sites involved in its development programs.
Buy or prescribe approved oncology drugs for patients with cancer.
End users of commercialized medicines, accessed through healthcare providers and reimbursement channels.
License, co-develop, or commercialize selected assets in defined geographies.
Use investigational products supplied for global and China studies.
Use distribution services provided through the joint venture business.
Strategia
The company’s strategy is to advance internally discovered oncology assets from research into commercialization, using partnerships to broaden reach while retaining key territorial rights where strategically important. It also supports this model with manufacturing control for selected products and with a distribution venture that adds non-core operating income in China.
Late-stage and earlier programs can expand the marketed portfolio and create future partnered or self-commercialized products.
Retaining rights in Mainland China and nearby markets preserves strategic value in the company’s core geography.
In-house and outsourced manufacturing support commercialization, supply continuity, and global launch readiness.
Commercial partners can broaden geographic reach and reduce the burden of direct commercialization.
Maantiede
HUTCHMED’s business is centered on China, where its marketed products and distribution activities are concentrated, while its development and commercialization footprint extends to Hong Kong, Macau, Taiwan, the U.S., Europe, and Japan. Manufacturing is anchored in Shanghai, with additional commercial supply supported by a third-party CDMO site in Switzerland for certain products.
Riskit
HUTCHMED’s risk profile is shaped by drug development uncertainty, regulatory approval dependence, and commercialization execution in highly competitive oncology markets. The business also faces manufacturing, partner, and reimbursement risks because much of its value depends on successful trials, regulatory clearances, and third-party commercial relationships.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug candidates may not demonstrate sufficient safety or efficacy in trials, which can eliminate expected product value.
Kohdistuu: Pipeline oncology and immunology assets
- Regulatory approval and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercialization depends on approvals and manufacturing inspections across multiple jurisdictions.
Kohdistuu - Partner dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Some key products are marketed or developed with partners, so execution and economics depend on third parties.
Kohdistuu - Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Korkea
Market access for oncology medicines can be affected by inclusion in reimbursement formularies and pricing negotiations.
Kohdistuu: China commercial market
- Manufacturing and supply disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Commercial supply relies on Shanghai production and select external CDMO capacity.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätUpfront, regulatory, and commercial milestone payments may be recognized at different times, affecting comparability across periods.
Vaikutus: Can create lumpy revenue and earnings
Partner commercialization can generate royalties tied to third-party net sales, making revenue dependent on external sales performance.
Vaikutus: Variable revenue stream
The distribution business and equity interest disposals can materially change reported earnings and revenue mix.
Vaikutus: Affects non-core income and margins
Research and development costs are typically incurred before revenue is realized, influencing operating results.
Vaikutus: Drives expense intensity
The company operates across currencies and jurisdictions, so translation effects can move comprehensive income.
Vaikutus: Impacts equity and OCI
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ascentage Pharma Group International - American Depository Shares
AAPG · Pharmaceutical Preparations
Ascentage Pharma Group International is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for cancer.
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Zhongchao Inc.
ZCMD · Services-Educational Services
Adlai Nortye Group Ltd.
ANL · Pharmaceutical Preparations
Pyxis Oncology, Inc.
PYXS · Pharmaceutical Preparations
Päivitetty: 28.9.2026